Notícias e Atividades da Corcept Therapeutics
Presença
A Corcept Therapeutics desenvolve e comercializa medicamentos para distúrbios metabólicos e endócrinos graves. Seus produtos e programas de pesquisa atendem hospitais, profissionais de saúde e pacientes que precisam de tratamentos relacionados a hormônios.
Visão geral dos produtos e serviços da Corcept Therapeutics:
- Medicamentos com prescrição
- Terapias hormonais
- Tratamentos metabólicos
- Terapias oncológicas
- Pesquisa clínica
Receita: ~$675 million
Funcionários: 500
Sede: Redwood City, Estados Unidos
Corcept Therapeutics é uma das ...
Corcept Therapeutics é uma empresa listada sob o símbolo CORT (US).
Executivos
Veja o organograma con seus 33 executivos principais
Biografias mais buscadas da Corcept Therapeutics
- Joseph Belanoff, Chief Executive Officer & Director
- Joshua Murray, Director
- Daniel Swisher, Director
Criar um alerta
para seguir os movimentos de executivos da Corcept Therapeutics.
Biotecnologia
Corcept Therapeutics possui 2.430 concorrentes concorrentes Lonza (Suíça), Vertex Pharmaceuticals (Estados Unidos) e Eurofins (Luxemburgo).
Popular M&A news in Biotecnologia
- Tempus has announced the acquisition of Personalis (publicado em 20 de julho de 2026).
- Eli Lilly has announced the acquisition of AtaiBeckley (publicado em 17 de julho de 2026).
- GSK adquiriu Nuvalent (publicado em 17 de julho de 2026).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Corcept Therapeutics
- Press Releases – Corcept Therapeutics, Incorporated
- Corcept Announces Results From Phase 2 Study of Dazucorilant in Patients With Amyotrophic Lateral Sclerosis (ALS) – Corcept Therapeutics, Incorporated
- Corcept’s Phase 3 Long-Term Extension Study of Relacorilant Demonstrated Durable Cardiometabolic Improvements in Patients with Hypercortisolism – Corcept Therapeutics, Incorporated
- Press Releases – Corcept Therapeutics, Incorporated
- Corcept Announces Positive Results in Treatment Phase of CATALYST Trial in Patients With Hypercortisolism (Cushing’s Syndrome) and Difficult-to-Control Diabetes – Corcept Therapeutics, Incorporated
- Corcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing’s Syndrome and Provides Corporate Update – Corcept Therapeutics, Incorporated
- Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call – Corcept Therapeutics, Incorporated
- Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update – Corcept Therapeutics, Incorporated
- Press Releases – Corcept Therapeutics, Incorporated
- Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call – Corcept Therapeutics, Incorporated
- View more press releases Close
Redes sociais sobre Corcept Therapeutics
- Corcept Therapeutics na Wikipedia, Google News e Yahoo Finance
- Corcept Therapeutics na LinkedIn, X (Twitter) e YouTube
